Calmark Sweden AB signs an agreement with Scandinavian CRO regarding consulting services for clinical studies

Calmark Sweden AB has today signed an agreement with Scandinavian CRO, a Clinical Research Organization with vast experience and deep knowledge in the field of clinical studies. The agreement covers consulting services regarding the planning and execution of clinical studies on Calmark's product Neo.

As part of the CE marking process for Calmark's product, pilot studies will be conducted on new-born infants in Sweden. After the CE marking has been obtained, more extensive clinical studies will be conducted in several countries. Calmark Sweden AB has therefore signed an agreement today with Scandinavian CRO (SCRO), headquartered in Uppsala. The agreement covers the provision of consulting services in the planning and execution of said studies, for instance assistance with administration and monitoring.

Scandinavian CRO specializes in medical technology products, and has more than 10 years of experience in the industry. The company is a full-service CRO, which means that it offers the entire chain of services, from the planning of clinical studies and the seeking of ethics approval, to practical implementation of studies and writing of reports. SCRO is the fastest-growing CRO in Scandinavia.

"We are looking forward to initiate work on the clinical studies of our products. Even though Calmark has a solid in-house expertise in clinical studies management, this is a hectic time for the company. In advance of the forthcoming clinical studies we have therefore chosen to enlist assistance, in particular with the administrative work. SCRO has an impressing track-record and long experience, and will be able to relieve our workload so that we can proceed more quickly. We are looking forward to getting down to work, together", says Anna Söderlund, CEO of Calmark.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 213 25 35


Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analyzis method with easier and faster sampling of medical conditions in newborns. The unique test platform, which consists of a reader and single-use products, is expected to be ready for launch in 2020 when three important POC tests are introduced. The WHO estimates that 1.5 billion children will be born worldwide by 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter healthcare chains. In less developed healthcare systems, the product helps save lives. Calmark aims to become the global leader and ultimately to offer all relevant POC tests for the first period of life, regardless of where in the world a baby is born. Read more about Calmark  



Documents & Links